Evaluation of the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706) in combination with bevacizumab for postoperative adjuvant treatment of HCC with high-risk recurrence risk
Voluntarily participate in this study and sign the informed consent form;
Age 18-100 years old, male or female;
Hepatocellular carcinoma confirmed by histopathology, cytology or imaging;
CNLC PHASE I-II;
It is known that there are fibrotic plate HCC, sarcomatoid HCC or mixed-type cholangiocarcinoma and HCC;
There is evidence of residual, recurrent or metastatic disease;
History of hepatic encephalopathy;
Previous receipt of allogeneic stem cell or solid organ transplantation, or on the waiting list for liver transplantation;